ANNEX. CHAPTER I General principles

Size: px
Start display at page:

Download "ANNEX. CHAPTER I General principles"

Transcription

1 ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I General principles Art (1) Clinical trials which are undertaken within Romania are authorised by the National Medicines Agency (NMA) in compliance with Law No. 95/2006 on healthcare reform, Title XVII The medicinal product. (2) Non-interventional studies are an exception to provisions of paragraph (1), as defined in the Norms relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, approved through Minister of Public Health Order No. 904/2006 on the approval of the Norms on the implementation of GMP rules in clinical trials carried out on medicinal products for human use, which shall be notified to the NMA. Art Clinical trials must be conducted in accordance with all regulations in force relating to clinical trials. CHAPTER II Authorisation procedures for clinical trials Art (1) In view of starting an authorisation procedure for a clinical trial, the applicant shall submit to the NMA, after having assessed the existence of all documents an application in the format of SCD No. 49/2006 provided in the Guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authority, notification of substantial amendments and declaration of the end of the trial in Romania, modified through SCD No. 27/ (2) On request, the documents mentioned in Annex 1 which is integral part of these regulations are attached. (3) Documentation must be provided in either English or Romanian. (4) The label of the medicinal products used in clinical trials (investigational medicinal product, reference medicinal product, placebo)

2 should be given in Romanian and English (only for the NMA use, so that the translation may be verified); clinical trials shall only use the label in Romanian, and if the sponsor/investigator is Romanian, the label may only be presented in Romanian. (5) The information for the subject and the informed consent form should be presented in Romanian (and in the language of ethnic minorities, if required) and in English, so that the translation may be verified by the NMA; in case the sponsor/investigator is Romanian, the information for the subject and the informed consent form should only be presented in Romanian. (6) The documents mentioned in Art. 3 (2) should be set up in accordance with the provisions of SCD No. 49/2006. Art (1) Documentation and Sample Admission Compartment of the Evaluation-Authorisation Department verifies the existence of all solicited documents according to Annex 1. (2) If the documentation presented by the applicant is not complete, the application for authorisation is suspended. (3) If the documentation is complete, the application is accepted and it shall receive a NMA registration number. Art. 5. The authorisation tariff for admission, established through the Minister of Public order in force, shall be paid after having accepted the application for authorisation. Art. 6. After the money enters into the NMA account, the evaluation procedure of the documentation needed in clinical trial authorisation shall start. Art (1) If, following evaluation of documentation, additional information is needed, the NMA shall thereof inform the applicant in writing. (2) The authorisation/rejection of the clinical trial authorisation is extended compared to the deadline mentioned in Minister of Public Health Order No. 904/2006 with the duration of time elapsed as of admission of the application letters containing applications issued by the applicant and until the NMA receipt of the solicited information. Art In case the documentation is set up in compliance with provisions of SCD No. 49/2006, the NMA forwards the authorisation for clinical trial conduct in the format shown in Annex 2 which is integral part of these Regulations, according to the term mentioned in Art. 39 of the Minister of Public Health Order No. 904/2006. Art Art If, following the documentation s evaluation, it is observed that it is not set up according to regulations in force and not

3 sufficiently justified, according to the term mentioned in the Minister of Public Health Order No. 904/2006, the applicant shall be informed by the NMA about the authorisation s rejection, which shall be accompanied by an evidence report. Art (1) The applicant may require the revision of the rejection decision in maximum 30 days as of the NMA decision being shown; the review request must be accompanied by support documentation. (2) The NMA shall analyse the application and then express its point of view in maximum 30 days as of admission to the NMA. Art. 11. The authorisation is valid during the conduct of a clinical trial, approved by the NMA; the trial shall start maximum 6 months after the date of the approval. Art A clinical trial may be started only if the NMA has not forwarded any motivated objections and after having obtained National Ethics Committee favourable opinion, in multicentre studies, or the Institutional Ethics Committee favourable opinion, in single-centre studies. CHAPTER III Importation of investigational medicinal products Art The notification of investigational medicinal products (IMPs) importation shall be done in compliance with legislation in force. CHAPTER IV Analysis of biological samples Art Analysis of biological samples collected during the clinical trials may be carried out in certified or accredited laboratories in Romania or other countries. Art. 15. In case the analysis of biological samples is not performed in Romania, these shall be sent to another member states/the exportation in third countries shall be done in compliance with legal provisions in force. CHAPTER V GCP inspection Art GCP inspection is conducted in accordance with legal provisions in force. CHAPTER VI Requests concerning ways of trial subjects recruitment

4 Art. 17. Recruitment of subjects for clinical trials conducted in Romania can only be done via advertisements/leaflets which can only be distributed in hospitals/medical cabinets; healthy volunteers may also be recruited via other means excepting the media. CHAPTER VII Reporting of adverse situations occurring in clinical trials Art. 18. It is the sponsor s obligation to report to the NMA adverse reactions and other information according to the provisions of SCD No. 26/2007 on the approval of the Guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use, occurring during clinical trials conducted at Romanian sites and on the electronic applications submitted by the NMA published on the EudraVigilance website. Art. 19. Serious suspected and unexpected adverse reactions, ending in death or life-threatening, shall be reported to the NMA only by the sponsor, in accordance with Minister of Public Health Order No. 904/2006. Art. 20. Reporting of adverse reactions occurring in clinical trials conducted in Romania shall be done according to the form of the Council for International Organisations of Medical Sciences, 2 nd version. Art. 21. In non-commercial studies, as defined in Minister of Public Health Order No. 904/2006, serious suspected and unexpected adverse reactions shall be reported to the NMA by the investigator within the time frames mentioned in the provisions of SCD No. 26/2007. CHAPTER VIII Requests on investigator s qualification Art. 22. Requests on investigator s qualification are mentioned in Art. 37 of the SCD 39/2006 on the approval of the Guideline on Good Clinical Practice. Art. 23. The application for authorisation of a clinical trial is accompanied by the form concerning qualification of each main investigator at the respective trial sites and his/her consent for participating in the clinical trial according to Annex 4, which is integral part of these Regulations. Art. 24. In case of non-commercial studies, the investigator who initiates the trial receives the responsibilities of the sponsor. CHAPTER IX Authorisation of institutions where clinical trials may be conducted

5 Art. 25. Clinical trials may be conducted only in institutions authorised by the Ministry of Public Health, in accordance with provisions of Minister of Public Health Order No. 912/2006 in force on approval of Regulations for authorisation of units which may carry out clinical trials on medicinal products for human use. Art. 26. The authorisation is granted by the Ministry of Public Health on request of the interested institution, in compliance with legal regulations in force. CHAPTER X Notification procedure for non-interventional studies Art. 27. The notification of non-interventional studies resides in submission by an applicant to the NMA of a notification address, made according to provisions of Annex 5, which is integral part of these Regulations, accompanied by the following documents: - copy of the study project; - list of the sites where the trial will be conducted; - information on the duration of the trial and number of patients who will enrol; - list of the investigators containing their names, surnames and workplaces; - trial objectives: a) The scientific objectives of the trial should be clearly stated, as well as the relevance for the medical practice of the data obtained during the trial s conduct; b) The assessment indicators of the trial objectives should be specified. Art. 28. The clinical trial proposer is responsible for transmitting to the NMA the results of the non-interventional study, as well as the interpretation and the statistical significance of results in one year after the cessation of the study. Art. 29. In case of non-interventional studies, the NMA does not request any tariff for the activity undertaken. Art. 30. The NMA shall host a particular database containing noninterventional studies which shall also contain the results of noninterventional trials carried out in Romania. Art. 31. In case the NMA hasn t submitted to the clinical trial proposer in written form the necessity of transmitting additional data in 60

6 days as of the notification s submission, the trial initiation notification is considered accepted and the trial may start. ANNEX 1 to Regulations DOCUMENTS accompanying the application for authorisation of a clinical trial to the NMA 1. General information 1.1. Confirmation of receipt of the EudraCT number 1.2. Covering letter 1.3. Application form 1.4. List of competent authorities (CA) in the EU to whom the application and the decision details have been submitted, when available 1.5. Copy of the Ethics Committee opinion, if available 1.6. Copy/summary of any scientific counselling 1.7. If the applicant is not the sponsor, a legal authorisation letter from the sponsor, allowing the applicant to act on behalf of the sponsor 1.8. Acceptance of the application in English 2. Information on the trial subjects 2.1. Informed consent form 2.2. Document containing information for the subject 2.3. Contracts of recruiting subjects 3. Information on the protocol 3.1. Protocol containing all amendments 3.2. Summary of the protocol in Romanian 3.3.Re-evaluation of the trial (Peer review), when available 3.4.Opinion of the main investigator/coordinator on the ethical aspects of the trial 4. Information on the investigational medicinal product (IMP) 4.1. Investigator s Brochure 4.2. Investigational Medicinal Product Simplified Dossier (IMPSD) 4.3. Simplified Investigational Medicinal Product Dossier (IMPD) 4.4. Summary of Product Characteristics (SPC) (for medicinal products which own a marketing authorisation in Romania or in the EU)

7 4.5. Information about all active clinical trials on the same IMP 4.6. If the IMP is manufactured in the EU and doesn t own an MA in the EU Copy of the manufacturing authorisation according to Art. 13 of Directive 2001/20/EC, mentioning the application field of the authorisation 4.7. If the IMP is not manufactured in the EU and doesn t have an MA in the EU Certification of the qualified person referring to the fact that the manufacturing site is compliant with the Good Manufacturing Practice (GMP)/at least equivalent to the GMP-EU or referring to the fact that each manufacturing batch has been submitted to testings, analysis or controls needed in view of confirming the quality GMP certificate for the active substance Copy of the manufacturing/importation authorisation in accordance with Art. 13 of Directive 2001/20/EC IMP analysis certificate in exceptional cases: When the impurities are not specifically justified or if unexpected impurities are justified, not covered by specification 4.9. Viral safety studies, if needed Applicable authorisations for trials or medicinal products having special features, such as genetically modified organisms (GMOs), radiopharmaceuticals TSE certificate, if needed Labelling examples in Romanian and English 5.Information on the staff and facilities 5.1. Facilities made available for the trial (Authorisation of the sanitary unit for the conduct of clinical trials, Consent of the sanitary unit s director on the conduct of the clinical trial) 5.2. CV of the coordinator-investigator in Romania (for multicentre trials) 5.3. CV of each investigator responsible for conducting the trial at Romanian investigational sites (main investigator) 5.4. Information about the support personnel (Form on the qualification of the main investigator)

8 ANNEX 2 to Regulations AUTHORISATION for the conduct of the clinical trial The National Medicines Agency, based on Art. 37 of the Minister of Public Health Order No. 904/2006, authorises the conduct of a clinical trial according to Protocol No.: EudraCT No.: Title: Sponsor: Investigators: Institution (trial site): Remarks: PRESIDENT,...

9 FORM for reporting severe suspected adverse reactions ANNEX 3 to Regulations Suspected adverse reaction Protocol No. Notification No. Investigational Medicinal Product Patient No. I. Information on the adverse reaction 1.Patient s initials 1.Country 2.Birthplace 2.a. Age 3. Sex Manifestation of the adverse reaction Day Month Year Day Month Year Reaction s description (including relevant outcomes/laboratory Fill in testings) accordingly: [ ] Death [ ] Lifethreatening [ ] Extension of hospitalisation [ ] Invalidating [ ] Congenital disorders/ cancer [ ] Other important requirements

10 II. Information about the suspected investigational medicinal product 14.Name of the investigational medicinal product 15. Daily dose 16. Route of administration 20. The adverse reaction has subsided after the discontinuation of the trial [ ] Yes [ ] No 21. The adverse reaction has reoccurred after the second administration of the investigational medicinal product [ ] Yes [ ] No 17. Administration indications 18. Period of administration (from/until) 19.Duration of the administration III. Simultaneous medication and history 22.Simultaneous medication and administration data (excluding that one meant for the reaction s treatment) 23. Other relevant anamnesis data (such as diagnosis, allergic reactions, pregnancy etc.) IV Information about the sponsor and the investigator 24.a. Name and address of the sponsor 24.b. Name of the investigator 24.c. Date of receipt by the sponsor 25.a. Type of information [ ] Initial [ ] Sequential 25.b. Manner of informing the sponsor Date of notification Date of receipt [ ] Additional information shall be attached Sponsor s signature

11 ANNEX 4 to Regulations FORM Concerning qualification of the main investigator/coordinator and arrangements made for participation in the clinical trial Investigational medicinal product... Protocol No.... Name of the main investigator/coordinator Investigator s address. Curriculum Vitae/summary:... YES [ ] Qualification.... Attached (profession) Experience in clinical trials:... Experience with other relevant medicinal products for the proposed trial Common tasks: Involvement in other clinical trials : Necessary time for this protocol: Availability of subjects suitable for the clinical trial: I hereby accept to participate as main investigator/coordinator in the clinical trial mentioned: I hereby agree to allow control of all documents: I hereby agree to allow access to basic documentation:

12 I hereby agree to sign the engagement form and conduct the trial according to the approved protocol, in compliance with the revised Declaration of Human Rights of Helsinki and Good Clinical Practice in Romania. During the trial, the following shall participate as sub-investigators : Signature Name Date... (day/month/year) Title (Monitor) ANNEX 5 to Regulations NOTIFICATION on the conduct of a non-interventional trial in Romania To the NATIONAL MEDICINES AGENCY APPLICANT SPONSOR INVESTIGATOR CRO* Name and surname Profession Institution Address Telephone/Fax number *) Contract Research Organisation We hereby inform you about the conduct of a non-interventional study for a medicinal product authorised for marketing in Romania: Title of the clinical trial :

13 - Country Information about the investigational medicinal product - Commercial name/code - Active substances - CTA code - Pharmaceutical form - Doses - Route of administration - Manufacturer This notification is accompanied by: Copy of the trial object Study objectives List of the sites where the trial shall be conducted; Information about the trial duration and number of patients to be enrolled. List of investigators containing the names and surnames of the investigators and their workplaces

RSC/CT Det. no. 1/2013

RSC/CT Det. no. 1/2013 RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please

More information

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive

More information

Submitting a CTA application to the MHRA

Submitting a CTA application to the MHRA This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

Clinical Trials application process, legislation & guidelines

Clinical Trials application process, legislation & guidelines Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission

More information

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE: Annex 1: Clinical trial Application Form REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE

More information

Regulatory and ethical requirements in medical devices studies. France

Regulatory and ethical requirements in medical devices studies. France Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

Agenzia Italiana del Farmaco

Agenzia Italiana del Farmaco Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP

More information

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing

More information

Regulatory and ethical requirements in medical device studies. Finland

Regulatory and ethical requirements in medical device studies. Finland Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within

More information

Regulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for

Regulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111

More information

Development Safety Update Report Guidance

Development Safety Update Report Guidance Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational

More information

Instruction document of the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain

Instruction document of the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain DEPARTMENT OF MEDICINAL PRODUCTS FOR HUMAN USE Instruction document of the and Medical Devices for conducting clinical trials in Spain Version 9 dated 22 nd February 2018 Date of publication: 24 April

More information

Clinical trials from CRA s point of view

Clinical trials from CRA s point of view Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines

More information

Belgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be

Belgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be Medicinal Products for Human Use - BELGIUM Competent authority Contact Details Contact Name 1 Federal Agency for Medicines and Health Products (FAMHP) / Agence Fédérale des Médicaments et des Produits

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical

More information

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical

More information

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products 1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible

More information

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014 20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

More information

A notice on the issuance of drug clinical trials, ethical review of the guiding principles

A notice on the issuance of drug clinical trials, ethical review of the guiding principles 药物临床试验伦理审查工作指导原侧.doc 的翻译 A notice on the issuance of drug clinical trials, ethical review of the guiding principles State Food and Drug Administration Note [2010] No. 436 November 2, 2010 Release A notice

More information

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS 1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS

More information

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials

Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Health Care Compliance Association Research Compliance Conference October 18-20, 2009 Minneapolis, MN 1 Today s Presenters

More information

Ethics and Clinical trials EU approach

Ethics and Clinical trials EU approach Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

GCP Basics - refresher

GCP Basics - refresher p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History

More information

Study Files and Filing

Study Files and Filing Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm

More information

Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB! if CCMO acts as CA:

Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO) NB!  if CCMO acts as CA: Medicinal Products for Human Use - NETHERLANDS Competent authority Contact Details Contact Name 1 Central Committee for Research Involving Human Subjects/ Centrale Commissie Mensgebonden Onderzoek (CCMO)

More information

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949 ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are

More information

EUROPEAN COMMISSION. ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals. Brussels, ENTR/CT 2. Revision 1

EUROPEAN COMMISSION. ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals. Brussels, ENTR/CT 2. Revision 1 EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/CT 2 Revision 1 Detailed guidance on the application format and documentation to be submitted

More information

Good Clinical Practice (GCP) & Clinical Trial Registries

Good Clinical Practice (GCP) & Clinical Trial Registries Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,

More information

Combined trial of an investigational medicinal product and an investigational medical device

Combined trial of an investigational medicinal product and an investigational medical device Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

Investigational Medicinal Product (IMP) Management Standard Operating Procedure Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Good Clinical Practice

Good Clinical Practice Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie

More information

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

Track III: International Clinical Trials: Global Compliance Norms and EU Focus Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health

More information

IMP Management and Accountability

IMP Management and Accountability This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012 New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public

More information

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents 2001L0018 EN 21.03.2008 003.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/18/EC OF THE EUROPEAN PARLIAMENT

More information

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act

More information

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015 REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE 02 December 2015 LAYOUT Background to clinical trials Stakeholders in clinical trials Legislative requirements

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Guidance for participating parties version 2.0, DISCLAIMER

Guidance for participating parties version 2.0, DISCLAIMER Voluntary Joint Pilot between FAMHP, the future College, accredited Ethics committees and sponsors for processing of applications for the authorisation of clinical trials and substantial modifications

More information

EU Clinical Trial Regulation A view from the Industry

EU Clinical Trial Regulation A view from the Industry Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty

More information

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)

Hospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee) Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research

More information

DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND

DISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare

More information

ICH/GCP Guidelines Self-Evaluation Questionnaire

ICH/GCP Guidelines Self-Evaluation Questionnaire THE QUALITY ASSURANCE JOURNAL, VOL. 2, 74 82 (1997) ICH/GCP Guidelines Self-Evaluation Questionnaire The questionnaire below has been designed as a diverting, internal training tool by a group of employees

More information

Investigator-Initiated INDs

Investigator-Initiated INDs Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.

More information

Brussels, C(2017) 8179 final. Guidelines

Brussels, C(2017) 8179 final. Guidelines EUROPEAN COMMISSION Brussels, 8.12.2017 C(2017) 8179 final Guidelines Detailed Commission guidelines on good manufacturing practice for investigational medicinal products for human use, pursuant to the

More information

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1 ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL Clinical Trial Application Form MEDICINES CONTROL COUNCIL APPLICATION TO CONDUCT A CLINICAL TRIAL Study title Protocol No. Version No. Study Drug MCC Ref. no. (if applicable) MCC Ref number(s) of comparator

More information

Competent federal higher authority ("Bundesoberbehörde- BOB")

Competent federal higher authority (Bundesoberbehörde- BOB) Nutrition/InterventionaI - GERMANY Competent authority Contact Details Contact Name 1 Competent federal higher authority ("Bundesoberbehörde- BOB") Contact Name 2 Federal Institute for Drugs and Medical

More information

The interface between Good Clinical Practice and Good Manufacturing Practice

The interface between Good Clinical Practice and Good Manufacturing Practice 1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who

More information

Recording, Managing and Reporting Adverse Events in the UK

Recording, Managing and Reporting Adverse Events in the UK This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document

More information

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008 Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...

More information

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition The rules governing medicinal products in the European Union Volume 2B Notice to Applicants Medicinal products for human use Presentation and content of the dossier 1998 Edition EUROPEAN COMMISSION Directorate

More information

Global Clinical Trial

Global Clinical Trial 1. Application For Global Clinical trial Sr. Contents 1. Name & Address of the Applicant:- 2. Name & Address of the Sponsor:- 3. Authorization Letter from Sponsor in favour of Applicant:- 4. Treasury Challan

More information

APPLICANT'S CHECKLIST

APPLICANT'S CHECKLIST APPLICANT'S CHECKLIST Research tissue bank (or other research biobank) REC Ref: Title of Tissue Bank: Applicant's Name: Name of Designated Individual: Please complete this checklist and send it with your

More information

National Health Surveillance Agency. Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017

National Health Surveillance Agency.  Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017 National Health Surveillance Agency www.anvisa.gov.br Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017 The Board of the National Health Surveillance Agency, in the use of the powers

More information

EXECUTIVE DIRECTOR OF THE EUROPEAN CHEMICALS AGENCY (ECHA) HELSINKI

EXECUTIVE DIRECTOR OF THE EUROPEAN CHEMICALS AGENCY (ECHA) HELSINKI EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL VACANCY NOTICE EXECUTIVE DIRECTOR OF THE EUROPEAN CHEMICALS AGENCY (ECHA) HELSINKI General description of tasks and role of the Agency The

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy

More information

PROTOCOL DRAFTING GUIDE

PROTOCOL DRAFTING GUIDE MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH

More information

Official Journal of the European Union. (Acts whose publication is obligatory)

Official Journal of the European Union. (Acts whose publication is obligatory) 5.11.2003 L 287/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1946/2003 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 15 July 2003 on transboundary movements of genetically modified organisms

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Medicinal Product quality, safety and efficacy Brussels, 16 August 2013 EudraLex The Rules Governing Medicinal

More information

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017 Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical

More information

Regulatory Requirements

Regulatory Requirements Regulatory Requirements CTTI Quality by Design Workshop 28-29 Jan 2013 Rockville, MD Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency An agency of the European Union Disclaimer

More information

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN

More information

HOSPITAL AUTHORITY (HA) GUIDE

HOSPITAL AUTHORITY (HA) GUIDE Page 1 of 14 HOSPITAL AUTHORITY (HA) GUIDE ON RESEARCH ETHICS (for Study Site & Research Ethics Committee) Revision Number: 1 (The document supersedes HA RE001 Hospital Authority Guide for Cluster Research

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)

SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the

More information

QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION

QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted

More information

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A) Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations

More information

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and

More information

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary

More information

Update on the IVDR. Sue Spencer

Update on the IVDR. Sue Spencer Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application

More information

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian Society

More information

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,

More information

EUROPEAN UNION. Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25

EUROPEAN UNION. Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25 EUROPEAN UNION THE EUROPEAN PARLIAMT THE COUNCIL Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: REGULATION

More information

Brexit Guidance for Stakeholders Human and veterinary medicines

Brexit Guidance for Stakeholders Human and veterinary medicines Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE

More information

VCU Faculty Held IND and IDE Procedure Handbook

VCU Faculty Held IND and IDE Procedure Handbook VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted

More information

Release into Environment of Genetically Modified Organisms Act 1

Release into Environment of Genetically Modified Organisms Act 1 Issuer: Riigikogu Type: act In force from: 01.07.2014 In force until: 31.07.2014 Translation published: 27.06.2014 Release into Environment of Genetically Modified Organisms Act 1 Amended by the following

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012

More information

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents 2003R1830 EN 11.12.2008 001.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B REGULATION (EC) No 1830/2003 OF THE EUROPEAN

More information

Writing an Assessment Report

Writing an Assessment Report Safeguarding public health Writing an Assessment Report Name: Malcolm Dash Date: Programme Why we need Assessment Reports Writing style Deficiency points Potential Serious Risk to Public Health Targeted

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research

Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research Standard Operating Procedures (SOPs) to achieve Good Clinical Practice (GCP) in Australian Clinical Research September 2007 Version 1.0 Prepared by Nucleus Network on behalf of VMIA Introduction to the

More information

The New EU IVDR. Overview of the Main Changes & Clinical Data Requirements. Advance Regulatory Consulting Ltd.

The New EU IVDR. Overview of the Main Changes & Clinical Data Requirements. Advance Regulatory Consulting Ltd. Overview of the Main Changes & Clinical Data Requirements Advance Regulatory Consulting Ltd. : Timeline: Entry in to force Q2 (Apr) 2017 Adoption: +6m NB s apply for designation IVDs classified as Class

More information

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells) European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand

More information

Structural Assistance Act

Structural Assistance Act Issuer: Riigikogu Type: act In force from: 01.09.2015 In force until: 04.12.2015 Translation published: 10.08.2015 Amended by the following acts Passed 04.06.2014 RT I, 21.06.2014, 1 Entry into force 01.07.2014

More information

Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS

Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS Key Topics Definitions Essential Principles Classification Conformity Assessment Framework License to Manufacture, Import,

More information